3 Mar 2021

Covaxin Prepared By Bharat Biotech Proves Efficacy Of 88%

Latest reports have been coming in from ICMR which has shared that 84 vaccine which is been made by Bharat biotech has demonstrated 81% efficiency in Phase 3 clinical trial.

As per reports coming in COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. 

The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR according to Bharat Biotech.

ICMR has stated that the results evaluated by an independent data safety and monitoring board, show that the vaccine (COVAXIN) is well-tolerated and efficacious against SARS-CoV-2 across a wide range of age groups and variants in the country.

The bench-to-bedside journey of completely indigenous COVID-19 vaccine (COVAXIN) in less than 8 months time showcases the immense strength of Atmanirbhar Bharat.

This strength of atmanirbharta Bharat helps to fight the odds and stand tall in the global public health community according to ICMR DG Dr Balram Bhargava.

No comments:

Post a Comment